About Hepion Pharmaceuticals

Hepion Pharmaceuticals (NASDAQ:HEPA) is a bio-pharmaceutical company focused on the development of drug therapies aimed at treating chronic liver diseases, including nonalcoholic steatohepatitis (NASH), hepatitis, and liver fibrosis. Central to its projects is CRV431, an experimental drug that shows promise in disrupting disease progression across multiple liver diseases. The company's objective is to advance these therapeutics through clinical trials to address the unmet medical needs in liver disease treatment. Beyond its leading candidate, Hepion is investing in a research and development pipeline that explores novel drug candidates and mechanisms for broader liver disease applications.

Snapshot

Public USOwnership

2013Year founded

22Employees

New Jersey, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Hepion Pharmaceuticals

CRV431 - A novel cyclophilin inhibitor designed for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
AI-POWR - An artificial intelligence platform used to enhance drug development, focusing on identifying novel drug candidates and optimizing clinical trial designs.
Liver Disease Research - Dedicated to the discovery and development of therapeutics for the treatment of liver diseases beyond NASH, such as fibrosis and hepatocellular carcinoma.
Drug Repurposing Program - Leverages their AI platform to identify new uses for existing drugs, aiming at rare and orphan diseases.
Collaborative Research Projects - Engages in partnerships with academic and research institutions to discover and develop new therapeutic approaches for liver diseases.

Hepion Pharmaceuticals executive team

Dr. Kaouthar Lbiati M.D.Interim CEO & Director
Sharen PyatetskayaDirector of Investor Relations